The Effect of Salt Water Nebulization on Cough, Sputum and Quality of Life in Chronic Obstructive Pulmonary Patients
NCT06519188 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 81
Last updated 2024-07-30
Summary
The aim of this clinical trial is to evaluate the effects of salt-water nebulization on individuals with chronic obstructive pulmonary disease. The main questions it aims to answer are:
Does salt-water application have an effect on cough and sputum management in individuals with COPD diagnosis? Does salt-water application have an effect on dyspnea management in individuals with COPD diagnosis? Does salt-water application have an effect on the quality of life in individuals with COPD diagnosis? The work was continued with two groups that did and did not practice. The group who made the application made the application twice a day every day for 2 months. The results of both groups were compared.
Conditions
Interventions
- OTHER
-
Nebulization application with 5 ml isotonic sodium chloride
Nebulization application with 5 ml isotonic sodium chloride in the morning and evening for two months.
Sponsors & Collaborators
-
Ministry of Health, Turkey
lead OTHER_GOV
Principal Investigators
-
ZELIHA ERMIS · MOH TURKEY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 35 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-02-28
- Primary Completion
- 2022-05-28
- Completion
- 2022-12-30
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
NCT00808288 ·Status: COMPLETED ·Phase: PHASE2
-
COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers
NCT02291016 ·Status: COMPLETED ·Phase: NA
-
Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00545311 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT02130635 ·Status: COMPLETED ·Phase: PHASE2
-
Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD
NCT03363503 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00856193 ·Status: COMPLETED ·Phase: PHASE2
-
Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)
NCT01721291 ·Status: COMPLETED ·Phase: PHASE4
-
Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Bronchiectasis
NCT01112410 ·Status: UNKNOWN ·Phase: PHASE2
-
Impulse Oscillometry in COPD Exacerbation
NCT07185581 ·Status: COMPLETED
-
Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
NCT03219866 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD
NCT00571428 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
NCT02459080 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
NCT02522299 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Fluticasone/Salmeterol Combination on Exertional Breathlessness in Patients With Mild COPD
NCT00559312 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients With COPD
NCT06643078 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD
NCT02347761 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
NCT01513460 ·Status: COMPLETED ·Phase: PHASE3
-
A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01316887 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD
NCT02233686 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Finding Study of CHF 4226 for Treating Patients With COPD
NCT00605891 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
NCT01072149 ·Status: COMPLETED ·Phase: PHASE3
-
Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01131806 ·Status: UNKNOWN ·Phase: PHASE4
-
Shortness Of Breath Questionnaire Validation Study
NCT00411372 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)
NCT00731822 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study
NCT01426009 ·Status: COMPLETED ·Phase: PHASE2